Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264019 | 0.75 | CRBN (0.46) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL3993881 | 0.70 | CRBN (0.45) | CRBNDDB1POLBHSD17B10 | |
| SCHEMBL9696657 | 0.66 | SLC6A4 (0.37) | — | |
| SCHEMBL28299870 | 0.65 | CRBN (0.50) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL27411171 | 0.65 | CRBN (0.50) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL2990979 | 0.65 | CRBN (0.50) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL11980707 | 0.64 | POLB (0.41) | CRBNPKMPOLBHSD17B10 | |
| SCHEMBL7204552 | 0.64 | CRBN (0.48) | CRBNDDB1PKM | |
| SCHEMBL9065010 | 0.62 | CRBN (0.47) | CRBNDDB1PKMPOLBHSD17B10 | |
| SCHEMBL28282616 | 0.61 | CRBN (0.42) | CRBNDDB1PKMPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-3394093-A1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | Modernatx, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| EP-3386484-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3324979-A2 | INFECTIOUS DISEASE VACCINES | ModernaTX, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017112943-A1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017099823-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| EP-3134131-A1 | NUCLEIC ACID VACCINES | ModernaTX, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| WO-2017019935-A1 | MULTIMERIC MRNA | MODERNATX, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2015164674-A1 | NUCLEIC ACID VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |